Study guide
Section 4.5: Patient Assessment & Physical Examination Interpretation
Saudi Pharmacist Licensure Examination SPLE - Pharmacist
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
Section 0.1: About the Saudi Pharmacist Licensure Examination (SPLE) Section 0.2: How to Study and Prep for the SPLE
2 Chapter 1: Basic Biomedical Sciences
Section 1.1: Human Physiology & Pathophysiology Foundations Section 1.2: Medical Biochemistry & Enzymology Section 1.3: Medical Microbiology & Immunology Section 1.4: Molecular Genetics & Pharmacogenomics Foundations
3 Chapter 2: Pharmaceutical Sciences
Section 2.1: Medicinal Chemistry & Structure-Activity Relationships (SAR) Section 2.2: Drug ADME (Absorption, Distribution, Metabolism, Excretion) Section 2.3: General Pharmacology: Mechanisms of Drug Action Section 2.4: General Toxicology: Overdose, Antidotes & Adverse Drug Reactions (ADRs) Section 2.5: Pharmacognosy: Natural Products & Dietary Supplements Section 2.6: Basic Pharmaceutics & Dosage Form Design Section 2.7: Biopharmaceutics & Drug Delivery Systems Section 2.8: Applied Pharmacokinetics (PK): One-Compartment Models Section 2.9: Non-linear and Multi-compartment Pharmacokinetics Section 2.10: Sterile Compounding: Techniques & Quality Standards Section 2.11: Non-sterile Compounding & Product Formulation Section 2.12: Pharmaceutical Calculations: Dosing and Strengths Section 2.13: Pharmaceutical Calculations: Dilutions and Reconstitution Section 2.14: Pharmaceutical Calculations: Osmolarity, Milliequivalents, and Alligations
4 Chapter 3: Social, Behavioral, and Administrative Sciences
Section 3.1: Saudi Arabian Healthcare System & Public Health Policies Section 3.2: Pharmacoepidemiology & Post-Marketing Drug Surveillance Section 3.3: Pharmacovigilance & Drug Safety Monitoring in Saudi Arabia Section 3.4: Pharmacoeconomic Principles & Cost-Benefit Analysis Section 3.5: Pharmacy Management, Inventory, and Operations Section 3.6: Saudi Pharmacy Law & SFDA Regulations Section 3.7: Biostatistics, Clinical Trial Design & Literature Evaluation Section 3.8: Professional Ethics, Communication, and Dispensing Systems
5 Chapter 4: Clinical Sciences
Section 4.1: Drug Information Services & Evidence-Based Medicine Section 4.2: Clinical Pharmacokinetics & Therapeutic Drug Monitoring (TDM) Section 4.3: Clinical Pharmacogenomics & Personalized Therapeutics Section 4.4: Disease Prevention, Wellness, and Immunization Schedules Section 4.5: Patient Assessment & Physical Examination Interpretation Section 4.6: Clinical Pharmacology: Cardiovascular Disorders Section 4.7: Clinical Pharmacology: Renal & Urological Disorders Section 4.8: Clinical Pharmacology: Respiratory & Pulmonary Disorders Section 4.9: Clinical Pharmacology: Endocrine & Metabolic Disorders Section 4.10: Clinical Pharmacology: Infectious Diseases & Antimicrobial Stewardship Section 4.11: Clinical Pharmacology: Neurological & Psychiatric Disorders Section 4.12: Clinical Pharmacology: Oncology, Immunology, and Hematology Section 4.13: Clinical Pharmacology: Gastrointestinal & Hepatic Disorders Section 4.14: Therapeutic Decision-Making in Special Populations (Geriatrics, Pediatrics, Pregnancy, Lactation)
Section 4.5: Patient Assessment & Physical Examination Interpretation
Key Takeaways Explain This Topic AI
An Absolute Neutrophil Count (ANC) below 500 cells/mcL defines severe neutropenia, which represents a critical risk for life-threatening infections.
Measured serum calcium must be corrected in patients with hypoalbuminemia using the corrected calcium equation to avoid misdiagnosing hypocalcemia.
Rapid correction of severe chronic hyponatremia (>8-12 mEq/L in 24 hours) can trigger irreversible osmotic demyelination syndrome (ODS).
An AST to ALT ratio greater than 2:1 is a key diagnostic marker indicating alcoholic liver disease over other forms of hepatocellular injury.
Last updated: July 2026
- Patient Assessment & Physical Examination Interpretation
- Interpretation of Vital Signs
Vital signs are baseline physiological measurements used to evaluate overall bodily function and acute clinical status.
Blood Pressure (BP) : Classified based on the 2017 ACC/AHA Hypertension guidelines:
Normal : < 120 / < 80 mmHg < 120 / < 80 \text{ mmHg} < 120/ < 80 mmHg .
Elevated : 120 – 129 / < 80 mmHg 120\text{–}129 / < 80 \text{ mmHg} 120 – 129/ < 80 mmHg .
Stage 1 Hypertension : 130 – 139 130\text{–}139 130 – 139 systolic OR 80 – 89 mmHg 80\text{–}89 \text{ mmHg} 80 – 89 mmHg diastolic.
Stage 2 Hypertension : ≥ 140 \ge 140 ≥ 140 systolic OR ≥ 90 mmHg \ge 90 \text{ mmHg} ≥ 90 mmHg diastolic.
Heart Rate (HR) : Normal adult range is 60–100 beats per minute (bpm) .
Tachycardia ( > 100 bpm > 100 \text{ bpm} > 100 bpm ) can be secondary to fever, dehydration, anemia, hyperthyroidism, or medications (e.g., albuterol, pseudoephedrine).
Bradycardia ( < 60 bpm < 60 \text{ bpm} < 60 bpm ) can occur in trained athletes, hypothyroidism, or secondary to beta-blockers, non-dihydropyridine CCBs, or digoxin.
Respiratory Rate (RR) : Normal adult range is 12–20 breaths per minute . Tachypnea ( > 20 > 20 > 20 ) is an early sign of respiratory distress, pulmonary embolism, metabolic acidosis, or sepsis.
Temperature : Normal core body temperature is 36.5°C to 37.5°C (97.7°F to 99.5°F). Fever is typically defined as a temperature ≥ 38.0 ∘ C \ge 38.0^\circ\text{C} ≥ 38. 0 ∘ C ( 100.4 ∘ F 100.4^\circ\text{F} 100. 4 ∘ F ).
Oxygen Saturation ( SpO 2 \text{SpO}_2 SpO 2 ) : Normal range is 95% to 100% on room air. Levels < 90 % < 90\% < 90% indicate hypoxemia requiring oxygen therapy.
Complete Blood Count (CBC) Interpretation
The CBC measures cellular components of blood and is essential for diagnosing anemia, infection, and clotting disorders.
Red Blood Cells (RBC), Hemoglobin (Hb), and Hematocrit (Hct) :
Normal Hb : Men: 13.5 – 17.5 g/dL 13.5\text{–}17.5 \text{ g/dL} 13.5 – 17.5 g/dL ; Women: 12.0 – 15.5 g/dL 12.0\text{–}15.5 \text{ g/dL} 12.0 – 15.5 g/dL . Low levels indicate anemia.
Mean Corpuscular Volume (MCV) : Reflects RBC size (Normal: 80 – 100 fL 80\text{–}100 \text{ fL} 80 – 100 fL ).
Microcytic Anemia ( M C V < 80 fL MCV < 80 \text{ fL} MC V < 80 fL ): Typically caused by iron deficiency, thalassemia, or chronic disease.
Macrocytic Anemia ( M C V > 100 fL MCV > 100 \text{ fL} MC V > 100 fL ): Typically caused by Vitamin B12 or folate deficiency, alcohol abuse, or drugs (e.g., methotrexate, hydroxyurea).
Platelets (Plt) : Normal range is 150,000 to 450,000/mcL . Thrombocytopenia ( < 150 , 000 < 150,000 < 150 , 000 ) increases bleeding risk. Severe risk occurs when Plt < 20 , 000 < 20,000 < 20 , 000 (spontaneous hemorrhage risk). Can be drug-induced (e.g., heparin-induced thrombocytopenia, linezolid).
White Blood Cells (WBC) : Normal range is 4,500 to 11,000/mcL . Leukocytosis ( > 11 , 000 > 11,000 > 11 , 000 ) indicates infection, inflammation, leukemia, or systemic corticosteroid therapy.
Differential & Left Shift : An increase in the percentage of band (immature) neutrophils ( > 10 % > 10\% > 10% ) is termed a "left shift" and strongly suggests an acute bacterial infection.
Absolute Neutrophil Count (ANC) : Calculated to assess infection risk in neutropenic patients (e.g., post-chemotherapy): A N C = W B C (cells/mcL) × % Neutrophils + % Bands 100 ANC = WBC \text{ (cells/mcL)} \times \frac{\% \text{Neutrophils} + \% \text{Bands}}{100} A NC = W BC (cells/mcL) × 100 % Neutrophils + % Bands
Neutropenia : A N C < 1 , 500 cells/mcL ANC < 1,500 \text{ cells/mcL} A NC < 1 , 500 cells/mcL .
Severe Neutropenia : A N C < 500 cells/mcL ANC < 500 \text{ cells/mcL} A NC < 500 cells/mcL (mandates protective precautions and empiric broad-spectrum antibiotics if fever is present).
Serum Electrolyte Interpretation
Sodium ( Na + \text{Na}^+ Na + ) : Normal range: 135–145 mEq/L .
Hyponatremia ( < 135 < 135 < 135 ): Can be hypervolemic (heart failure, cirrhosis), euvolemic (SIADH), or hypovolemic (diuretic use, vomiting). Severe acute hyponatremia causes cerebral edema. Clinical Safety : Correcting sodium too rapidly ( > 8 – 12 mEq/L > 8\text{–}12 \text{ mEq/L} > 8 – 12 mEq/L in 24 hours) risks Osmotic Demyelination Syndrome (ODS) (formerly central pontine myelinolysis), causing irreversible neurological damage.
Hypernatremia ( > 145 > 145 > 145 ): Caused by water deficit or diabetes insipidus.
Potassium ( K + \text{K}^+ K + ) : Normal range: 3.5–5.0 mEq/L .
Hyperkalemia ( > 5.0 > 5.0 > 5.0 ): Caused by renal failure, potassium-sparing diuretics, ACEIs/ARBs, and NSAIDs. ECG changes: peaked T waves, prolonged PR interval, QRS widening, and flat P waves. Treatment: IV Calcium Gluconate (stabilizes cardiac membrane), Insulin + Dextrose (shifts potassium intracellularly), and Sodium Bicarbonate or Albuterol.
Hypokalemia ( < 3.5 < 3.5 < 3.5 ): Caused by loop/thiazide diuretics or vomiting. ECG changes: flat T waves, ST depression, and U waves. Exacerbates digoxin toxicity.
Calcium ( Ca 2 + \text{Ca}^{2+} Ca 2 + ) : Normal range: 8.5–10.5 mg/dL .
Corrected Calcium : Calcium is 50% bound to albumin. In patients with hypoalbuminemia, measured calcium is falsely low. Corrected calcium must be calculated: Corrected Calcium = Measured Calcium (mg/dL) + 0.8 × ( 4.0 − Albumin [g/dL] ) \text{Corrected Calcium} = \text{Measured Calcium (mg/dL)} + 0.8 \times (4.0 - \text{Albumin [g/dL]}) Corrected Calcium = Measured Calcium (mg/dL) + 0.8 × ( 4.0 − Albumin [g/dL] )
Magnesium ( Mg 2 + \text{Mg}^{2+} Mg 2 + ) : Normal range: 1.5–2.5 mEq/L . Hypomagnesemia predisposes to hypokalemia and hypocalcemia, and causes Torsades de Pointes.
Renal and Hepatic Function Assessment
Renal Function Tests :
Blood Urea Nitrogen (BUN) : Normal: 7 – 20 mg/dL 7\text{–}20 \text{ mg/dL} 7 – 20 mg/dL .
Serum Creatinine (SCr) : Normal: 0.6 – 1.2 mg/dL 0.6\text{–}1.2 \text{ mg/dL} 0.6 – 1.2 mg/dL .
BUN:Cr Ratio : A ratio > 20 : 1 > 20:1 > 20 : 1 indicates prerenal acute kidney injury (renal hypoperfusion/dehydration) because urea is reabsorbed with water while creatinine clearance remains relatively stable. In intrinsic renal injury, the ratio is typically 10 – 15 : 1 10\text{–}15:1 10 – 15 : 1 .
Hepatic Function Tests (LFTs) :
Hepatocellular Injury : Elevated Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST). ALT is more liver-specific. An AST:ALT ratio > 2 : 1 > 2:1 > 2 : 1 suggests alcoholic liver disease.
Cholestatic Pattern : Elevated Alkaline Phosphatase (ALP) and Gamma-Glutamyl Transferase (GGT) indicate biliary tract obstruction or drug-induced cholestasis.
Synthetic Function : Albumin (decreased in chronic liver disease) and Prothrombin Time/INR (prolonged in liver dysfunction because the liver synthesizes clotting factors II, VII, IX, and X).
Lab Test Normal Reference Range Clinical Significance of Elevation Clinical Significance of Decrease
Hemoglobin M: 13.5-17.5; F: 12.0-15.5 g/dL Polycythemia, chronic hypoxia Anemia (microcytic/macrocytic), bleeding
- Platelets 150,000 - 450,000 /mcL Thrombocytosis, inflammation Thrombocytopenia (bleeding risk)
- ANC 1,500 - 8,000 /mcL Infection, corticosteroid use Neutropenia (infection risk, ANC < 500 severe)
- Sodium 135 - 145 mEq/L Dehydration, diabetes insipidus SIADH, fluid overload (correct slowly to avoid ODS)
- Potassium 3.5 - 5.0 mEq/L Renal failure, ECG changes (peaked T) Diuretics, ECG changes (U waves)
- Serum Creatinine 0.6 - 1.2 mg/dL Acute or chronic kidney injury Muscle wasting, cachexia
- AST / ALT < 40 / < 50 U/L Hepatocellular injury (AST:ALT > 2:1 alcoholic) Generally not clinically significant
- PT / INR PT: 11-13.5s; INR: 0.8-1.2 Liver failure, warfarin therapy Hypercoagulable states